Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.
Martin D. McCarter(University of Colorado Cancer Center), William A. Robinson(University of Colorado Anschutz Medical Campus), Karl D. Lewis(University of Colorado Denver), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), Theresa Medina(University of Colorado Cancer Center), Kasey L. Couts(University of Colorado Anschutz Medical Campus), Richard P. Tobin(Society of Surgical Oncology), Dexiang Gao(University of Colorado Cancer Center), Victoria Nuanes(University of Colorado Anschutz Medical Campus), Robert J. Van Gulick(University of Colorado Anschutz Medical Campus), Dana M. Davis(Dalhousie University), Ross W. McFarland(Cancer Clinic), René González(University of Miami), Victoria M. Vorwald(University of Colorado Anschutz Medical Campus), Dasha T. Cogswell(University of Colorado Anschutz Medical Campus)
Cited by 4
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k